UCB is a global biopharmaceutical company dedicated to discovering and developing treatments that aim to transform the lives of people living with neurological and immunological conditions.
Because there is no such thing as an ‘average patient’ we use the tools, channels and scientific advances at our disposal to develop a deep understanding of a disease and the real needs of patients.
The UK is home to one of UCB's two state-of-the art global discovery research centres. We have around 500 scientists working independently and in collaboration with leading researchers from academia, medical charities and industry to deliver cutting-edge science, innovative drugs and practical solutions patients need to improve their quality of life.
As a top five investor in biopharmaceutical R&D in the UK UCB is proud of the collaborations we have with universities, charities, companies, patients and the NHS that enable us to reach for our ambition of transforming people’s lives.
​
UCB has no influence over the educational content of the St John’s DermAcademy.
We are inspired by patients. Driven by science.
For more information visit ucbpharma.co.uk